Baseline and treatment-induced chromosomal abnormalities in peripheral blood lymphocytes of Hodgkin's lymphoma patients

International Journal of Radiation Oncology Biology Physics

Volumn 57, Issue 2, 2003, Pages 321-326

  M'kacher, R ^a   Girinsky, T ^a   Koscielny, S ^a   Dossou, J ^a   Violot, D ^a   Beron Gaillard N ^a   Ribrag, V ^a   Bourhis, J ^a   Bernheim, A ^a   Parmentier, C ^a   Carde, P ^a  

^a INSTITUT GUSTAVE ROUSSY   (France)

Author keywords

Chromosomal abnormalities; Complex chromosomal rearrangements; FISH; Hodgkin's lymphoma

Indexed keywords

ABERRATIONS; BIOLOGICAL RADIATION EFFECTS; CHEMOTHERAPY; CHROMOSOMES; GENETIC ENGINEERING; IRRADIATION; PATIENT TREATMENT;

CHROMOSOMAL ABERRATIONS;

ONCOLOGY;

ANTINEOPLASTIC AGENT; BLEOMYCIN; CYCLOPHOSPHAMIDE; DACARBAZINE; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; PREDNISONE; PROCARBAZINE; VINBLASTINE; VINCRISTINE;

ADULT; AGED; ARTICLE; BLOOD; CANCER CHEMOTHERAPY; CANCER PATIENT; CHROMOSOME 1; CHROMOSOME 3; CHROMOSOME 4; CHROMOSOME ABERRATION; CHROMOSOME REARRANGEMENT; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; CORRELATION ANALYSIS; CYTOGENETICS; DISEASE ASSOCIATION; DRUG INDUCED DISEASE; EVOLUTION; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; FOLLOW UP; HODGKIN DISEASE; HUMAN; IRRADIATION; LIVING DONOR; LYMPHOCYTE; MALE; OBSERVATION; PAINTING; PERIPHERAL LYMPHOCYTE; POPULATION; PRIORITY JOURNAL; RADIATION DOSE; RADIATION FIELD; STATISTICAL SIGNIFICANCE;

EID: 0041381267     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0360-3016(03)00578-9     Document Type: Article

References (25)

1. Mendenhall N.P., Hoppe R.T., Prosnitz L.R., et al. Principles of radiation therapy in Hodgkin's disease. Mauch P.M., Armitage J.O., Diehl V., et al. Hodgkin's disease. 1999;465-478 Lippincott Williams & Wilkins, Philadelphia.
2. Van Leeuwen FE, Klokman WJ, Hagenbeek LA, et al. Second cancer risk following Hodgkin's disease: A 20-year follow-up study. J Clin Oncol 1994;12:312-325.
3. Holm G., Mellstedt H., Bjorkholm M., et al. Lymphocyte abnormalities in untreated patients with Hodgkin's disease. Cancer. 37:1976;751-762.
4. Tullgren O., Grimfors G., Holm G., et al. Lymphocyte abnormalities predicting a poor prognosis in Hodgkin's disease A long-term follow-up . Cancer. 68:1991;768-775.
5. Barrios L., Caballin M.R., Miro R., et al. Chromosome abnormalities in peripheral blood lymphocytes from untreated Hodgkin's patients A possible evidence for chromosome instability . Hum Genet. 78:1988;320-324.
6. Tilly H., Bastard C., Delastre T., et al. Cytogenetic studies in untreated Hodgkin's disease. Blood. 77:1991;1298-1304.
7. Ladanyi M., Parsa N.Z., Offit K., et al. Clonal cytogenetic abnormalities in Hodgkin's disease. Genes Chromosom Cancer. 3:1991;294-299.
8. Lalic H., Radosevic-Stasic B., Volavsek C. High incidence of chromosome aberrations after radiochemotherapy for Hodgkin's disease A report of a case and a review of the literature . Folia Biol (Praha). 47:2001;101-105.
9. Pinkel D., Straume T., Gray J.W. Cytogenetic analysis using quantitative, high-sensitivity, fluorescence hybridization. Proc Natl Acad Sci USA. 83:1986;2934-2938.
10. Savage J.R. Classification and relationships of induced chromosomal structural changes. J Med Genet. 13:1976;103-122.
11. M'Kacher R., Schlumberger M., Legal J.D., et al. Biologic dosimetry in thyroid cancer patients after repeated treatments with iodine-131. J Nucl Med. 39:1998;825-829.
12. Lucas J.N., Tenjin T., Straume T. II, et al. Rapid human chromosome aberration analysis using fluorescence in situ hybridization. Int J Radiat Biol. 56:1989;35-44.
13. Bender M.A., Preston R.J., Leonard R.C., et al. Chromosomal aberration and sister-chromatid exchange frequencies in peripheral blood lymphocytes of a large human population sample. II. Extension of age range. Mutat Res. 212:1989;149-154.
14. M'Kacher R., Legal J.D., Schlumberger M., et al. Sequential biological dosimetry after a single treatment with iodine-131 for differentiated thyroid carcinoma. J Nucl Med. 38:1997;377-380.
15. Dossou J., Lartigau E., M'Kacher R., et al. Biological dosimetry after total body irradiation (TBI) for hematologic malignancy patients. Int J Radiat Oncol Biol Phys. 46:2000;123-129.
16. Glick J, Tsiatis R, Schilsky T, et al. A randomised phase III trial of MOPP/ABV hybrid vs sequential MOPP/ABV in advanced Hodgkin's disease: Results of the inter-group trial [Abstract]. Presented at the Fifth International Conference on Malignant Lymphoma, Lugano, 1993.
17. Brandriff B.F., Meistrich M.L., Gordon L.A., et al. Chromosomal damage in sperm of patients surviving Hodgkin's disease following MOPP (nitrogen mustard, vincristine, procarbazine, and prednisone) therapy with and without radiotherapy. Hum Genet. 93:1994;295-299.
18. Duggan D.B., Petroni G.R., Johnson J.L., et al. Randomized comparison of ABVD and MOPP/ABV hybrid for the treatment of advanced Hodgkin's disease Report of an intergroup trial . J Clin Oncol. 21:2003;607-614.
19. Sen P., Bailey N.M., Hagemeister F.B., et al. Induction of chromosome breaks and sister chromatid exchanges in patients with Hodgkin's disease by two combination chemotherapy regimens of different leukemogenic potential. Cancer Res. 50:1990;558-562.
20. Tesch H., Diehl V., Lathan B., et al. Moderate dose escalation for advanced stage Hodgkin's disease using the bleomycin, etoposide, adriamycin, cyclophosphamide, vincristine, procarbazine, and prednisone scheme and adjuvant radiotherapy A study of the German Hodgkin's Lymphoma Study Group . Blood. 92:1998;4560-4567.
21. Aplan P.D., Chervinsky D.S., Stanulla M., et al. Site-specific DNA cleavage within the MLL breakpoint cluster region induced by topoisomerase II inhibitors. Blood. 87:1996;2649-2658.
22. Rudin C.M., Thompson C.B. Transcriptional activation of short interspersed elements by DNA-damaging agents. Genes Chromosom Cancer. 30:2001;64-71.
23. Ayoub J.P., Palmer J.L., Huh Y., et al. Therapeutic and prognostic implications of peripheral blood lymphopenia in patients with Hodgkin's disease. Leuk Lymphoma. 34:1999;519-527.
24. Doloy M.T., Malarbet J.L., Guedeney G., et al. Use of unstable chromosome aberrations for biological dosimetry after the first postirradiation mitosis. Radiat Res. 125:1991;141-151.
25. Van Leeuwen F.E., Swerdlow A.J., Valagussa P., et al. Second cancers after treatment of Hodgkin's disease. Mauch P.M., Armitage J.O., Diehl V., et al. Hodgkin's disease. 1999;607-632 Lippincott Williams & Wilkins, Philadelphia.